Bowmed Ibisqus
- Company typePrivate
- Founded2005
- HeadquartersChirk, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Bowmed Ibisqus firmographics
Firmographics- Name
- Bowmed Ibisqus
- Legal name
- Bowmed Ibisqus Ltd
- Website
- https://bowmed.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Bowmed Ibisqus industry classification
Industry- Product category
- Generic Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industries
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Bowmed Ibisqus is headquartered
LocationHeadquarters
- HQ city
- Chirk
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Bowmed Ibisqus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Generic Injectable Medicines Sales: Revenue is generated through the sale of generic injectable pharmaceutical products including antibiotics (penicillins, cephalosporins, carbapenems), cardiovascular drugs, anaesthetics, and gastrointestinal medicines to NHS hospitals and private healthcare providers.
- Distribution & Market Access Services: The company offers distribution support, market access consultancy, dossier trade and in-licensing, and product divestment services to pharmaceutical partners seeking UK market entry or expansion.
- Product Licensing Agreements: Bowmed distributes products on behalf of Marketing Authorization Holders including Laboratórios Azevedo, Villerton Invest, Quimedical-Produtos Farmaceuticos, and Ibigen Srl, operating in an in-licensing model where products are launched under MA holder approval.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels4 records
Bowmed Ibisqus product offering
Product offeringCore offering
Bowmed Ibisqus supplies generic injectable pharmaceutical products to NHS hospitals and the UK private healthcare sector. Its portfolio spans antibacterial injectables (penicillins, cephalosporins, carbapenems, quinolones, macrolides, glycopeptides, lincosamides), gastrointestinal injectables (PPIs), cardiovascular drugs, anaesthesia agents, and analgesics, distributed in ampoule, vial, and ready-to-use infusion bag formats. The company also offers distribution support, market access consultancy, dossier trade and in-licensing, and product divestment services to pharmaceutical partners.
Product overview
Bowmed Ibisqus is a privately owned pharmaceutical company and a wholly owned subsidiary of the Ibigen Group (Italy), specialising in the supply of generic injectable medicines to NHS hospitals and the private healthcare sector. The company offers a broad portfolio of injectable antibacterial medicines including penicillins (Amoxicillin, Flucloxacillin, Co-amoxiclav), cephalosporins (Cefotaxime, Ceftazidime, Ceftriaxone, Cefuroxime), carbapenems (Meropenem, Ertapenem), quinolones (Levofloxacin, Ciprofloxacin), macrolides (Clarithromycin), and other antibiotics (Vancomycin, Teicoplanin, Clindamycin). The portfolio has expanded into Gastrointestinal (Esomeprazole, Omeprazole, Pantoprazole), Cardiovascular (Amiodarone, Labetalol, Dopamine, Tirofiban), and Anaesthesia (Levobupivacaine, Ropivacaine, Sugammadex, Rocuronium) therapeutic areas. Products are available in multiple formats: ampoules, vials, and ready-to-use infusion bags. The company also provides value-added services including distribution support, market access consultancy, dossier trade and in-licensing, and product divestment services. Business partners include AAH Pharmaco (distribution), Masters Global, AIT Worldwide Logistics (transport), Fannin Ireland (Irish market), TPS Healthcare Group, and Movianto (Northern Ireland supply chain).
Differentiator
Problem solved
Functional benefit
Products and services
- Antibacterial Injectable Medicines
- Gastrointestinal Injectable Medicines
- Cardiovascular Injectable Medicines
- Anaesthesia Injectable Medicines
- Analgesic Injectable Medicines
- Antifungal and Antiviral Injectable Medicines
- Distribution Support Services
- Market Access Consultancy Services
- Dossier Trade and In-Licensing Services
- Product Divestment Services
Quantifiable outcome
- Substantial budgetary savings for NHS while safeguarding patient care
- +2 more outcomes
Companies that use Bowmed Ibisqus
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles3 records
Bowmed Ibisqus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bowmed Ibisqus partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- Fannin IrelandcorePartnership since 2018 to bring Bowmed's range of acute-care medicines to the Irish market, characterised by exceptional service, reliability, and partnership.
- TracelinkcorePartnership between IBI Lorenzini and Tracelink to implement global serialisation solutions ahead of the February 2019 FMD deadline. The flexibility, scalability, speed and efficiency of Tracelink EU hub met the IBI group's stringent track and trace requirements.
- Ibigen GroupflagshipBowmed Ibisqus is a wholly owned subsidiary of the Ibigen Group, headquartered in Italy. The group has over 100 years of experience producing and distributing injectable products worldwide, recognised for expertise in aseptic dosing and β-lactam formulations. The group operates as fully integrated, managing product development, regulatory registration, raw material sourcing, finished product manufacturing, and sales distribution.
- AAH PharmacocoreNominated distribution partner for Bowmed Ibisqus for several years, providing high level of service for Bowmed and ultimately for customers who use Bowmed products. The partnership strives to achieve the best possible standards.
- TPS Healthcare GroupcoreLong-standing strategic partnership for pre-wholesaler and distribution services throughout the UK for 18 years. The relationship ensures consistently high levels of service for supply of critical medicines to UK patients.
- Movianto Northern IrelandcorePartnership for over 15 years providing reliable, proactive and collaborative supply chain solution for Northern Ireland. The Movianto team provides additional support to assist with unforeseen market demands.
- Masters GlobalminorPartnership focused on improving access across emerging markets. Masters Global values Bowmed's communication, proactiveness, engagement, and product quality.
- AIT Worldwide LogisticsminorLong-standing transport company partner working with Bowmed for many years. AIT provides transport services ensuring products arrive to patients without changes to characteristics during transport, dealing with international supply chain challenges compliantly with forward planning.
- IntersyscoreDedicated cyber security provider maintaining Bowmed's certification and best practice standards. Provides 24/7 monitoring, threat detection, and incident response through a Security Operations Centre (SOC).
- UK Government Cyber Essentials SchemecoreBowmed Ibisqus is an early adopter of the UK government's Cyber Essentials scheme, demonstrating long-standing commitment to foundational security controls as a proactive defence against common cyber threats.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Bowmed Ibisqus competitors and assessment
Company assessmentBroad incumbents
- Pfizer (Hospira): Global pharmaceutical incumbent with a leading generic injectable portfolio (formerly Hospira) sold broadly into NHS hospitals. A broader incumbent in the same category as Bowmed's products, providing competitive context on pricing and supply continuity.
- Sandoz (Novartis): World's largest generics company with a broad injectable portfolio, including antibiotics and hospital therapies. A broad incumbent competitor in the UK generic injectable category.
- Viatris (Mylan): Large global generic and specialty manufacturer with a significant injectable and biosimilar portfolio serving UK hospitals. Operates in the same generic injectable space as Bowmed but at much greater scale and breadth.
Direct peers
- Hikma Pharmaceuticals: Major global manufacturer and supplier of generic injectable medicines with a strong UK hospital footprint. Directly comparable to Bowmed Ibisqus in product category, target customer (NHS secondary care), and broad anti-infective / hospital therapy portfolio.
- hameln pharma: Specialist European generic injectable pharmaceutical company supplying hospital markets including the UK. Closely comparable business model (generic injectables for hospital secondary care) and therapeutic focus on anaesthesia, analgesia, and critical care.
- Flynn Pharma: UK-headquartered specialty pharmaceutical company focused on supplying niche and generic medicines to the NHS and private healthcare. Comparable as a UK-anchored, sales-and-distribution-led generic pharmaceutical company serving secondary care.
- Mercury Pharmaceuticals (Advanz Pharma): UK-based specialty pharmaceutical company focused on hospital and specialty care products, including injectables. Comparable in the UK secondary care channel and in-licensing/distribution-led model.
- Ethypharm (Martindale Pharma): European specialty and generic injectable company with strong UK hospital presence (formerly Martindale Pharma). Directly comparable in generic injectable portfolio and NHS secondary care customer base.
Others
- AAH Pharmaceuticals: UK's largest pharmaceutical distributor and Bowmed's nominated UK distribution partner. Comparable as a critical channel for Bowmed's products and as a participant in the same NHS secondary care supply chain.
- TPS Healthcare Group: UK pre-wholesaler and distribution partner of Bowmed Ibisqus for 18 years. Comparable as a long-tenured distribution channel serving UK hospital customers and as a benchmark for supply chain partnerships in this category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bowmed Ibisqus compliance and trust
Trust signalCompliance2 records
Bowmed Ibisqus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bowmed Ibisqus leadership team
Management profileNumber of profiles
Profiles1 record
Bowmed Ibisqus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bowmed Ibisqus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bowmed Ibisqus
What does Bowmed Ibisqus do?
Bowmed Ibisqus supplies generic injectable pharmaceutical products to NHS hospitals and the UK private healthcare sector. Its portfolio spans antibacterial injectables (penicillins, cephalosporins, carbapenems, quinolones, macrolides, glycopeptides, lincosamides), gastrointestinal injectables (PPIs), cardiovascular drugs, anaesthesia agents, and analgesics, distributed in ampoule, vial, and ready-to-use infusion bag formats. The company also offers distribution support, market access consultancy, dossier trade and in-licensing, and product divestment services to pharmaceutical partners.
Is Bowmed Ibisqus a public or private company?
Bowmed Ibisqus is a private company. It is classified as corporate owned and is currently operating.
When was Bowmed Ibisqus founded?
Bowmed Ibisqus was founded in 2005. It employs 1 to 10 people.
Where is Bowmed Ibisqus based?
Bowmed Ibisqus is headquartered in Chirk, United Kingdom, in the Europe region.
How does Bowmed Ibisqus make money?
Three revenue lines are on record. Generic Injectable Medicines Sales are the primary driver. The others are distribution & Market Access Services and product Licensing Agreements.
Who are Bowmed Ibisqus's main competitors?
Broad incumbents on record are Pfizer (Hospira), Sandoz (Novartis) and Viatris (Mylan). Direct peers are Hikma Pharmaceuticals, hameln pharma, Flynn Pharma, Mercury Pharmaceuticals (Advanz Pharma) and Ethypharm (Martindale Pharma). Others are AAH Pharmaceuticals and TPS Healthcare Group.
Does Bowmed Ibisqus have an API?
No public API is recorded for Bowmed Ibisqus.
What industry is Bowmed Ibisqus in?
Bowmed Ibisqus's product category is Generic Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.